Search results for "Prevention"

showing 10 items of 1662 documents

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.

2021

Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…

COUNTRIESmedicine.medical_specialtyDyslipidaemiaAtherosclerosis; Cardiovascular; Dyslipidaemia; Low-density lipoprotein cholesterolCardiac & Cardiovascular SystemsIMPACTDYSLIPIDEMIACardiovascularGUIDELINESLipid-lowering therapySecondary CareSecondary careRisk FactorsCARDIOVASCULAR RISK-FACTORSMANAGEMENTMedicineHumansLow-density lipoprotein cholesterolCORONARY-HEART-DISEASE1102 Cardiorespiratory Medicine and HaematologyDyslipidemiasSecondary preventionLipid managementScience & Technologybusiness.industryDisease mortality1103 Clinical SciencesAtherosclerosisPREVENTIONLipidsPREVALENCEClinical PracticeEuropeCross-Sectional StudiesTreatment OutcomePeripheral Vascular DiseaseCardiovascular System & HematologyCardiovascular DiseasesFamily medicineEuropean atherosclerosis societyCardiovascular System & CardiologyObservational studyPolandHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineAtherosclerosis
researchProduct

Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond : why and how : a position statement from the Secondary Pr…

2021

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com

Canadamedicine.medical_specialtyEpidemiologymedicine.medical_treatmentCardiologyDisease030204 cardiovascular system & hematologySDG 3 – Goede gezondheid en welzijn03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingSecondary PreventionmedicineHumansAerobic exercisePulmonary rehabilitationMedical prescription610 Medicine & healthlääkinnällinen kuntoutusBiologyAerobic trainingCardiac RehabilitationRehabilitationkuntoliikuntabusiness.industry030229 sport sciences Cardiovascular rehabilitationaerobinen harjoitteluExercise TherapyResistance trainingPrescriptionsCardiovascular rehabilitationsydän- ja verisuonitauditExercise intensityPhysical therapyPosition paperkuntoutusvoimaharjoitteluHuman medicineCardiology and Cardiovascular MedicinebusinessExercise intensityliikuntahoitoCardiovascular rehabilitation
researchProduct

The effects of the financial crisis on primary prevention of cancer

2010

The present financial crisis will affect primary cancer prevention through several avenues: personal lifestyle choices, exposure to environmental risk factors, decisions made in the private sector and public policy on cancer prevention. Whilst it is clearly problematic to reach solid conclusions on a direct connection between economic crises and cancer mortality, we can identify trends that provide guidance for further action. For some lifestyle choices such as smoking or diet, we argue that public policy may channel existing tendencies during times of crisis for clear added value. In other areas, including research and health system investments, we will make the case that the resources not…

Cancer ResearchBiomedical ResearchAlcohol Drinkingmedia_common.quotation_subjectPublic policyRecessionFinancial managementRisk FactorsNeoplasmsOccupational ExposureHumansMedicineExerciseLife StyleHealth policymedia_commonInsurance HealthCancer preventionPublic economicsbusiness.industrySmokingVaccinationEnvironmental ExposureEnvironmental exposureHealth ServicesPrivate sectorDietEuropePrimary PreventionEconomic RecessionOncologyFinancial crisisPrivate SectorHealth ExpendituresbusinessDelivery of Health CareEuropean Journal of Cancer
researchProduct

Making progress against cancer in Europe in 2008.

2008

Europe is facing a cancer epidemic, with rapidly increasing incidence rates. Population growth and ageing will further increase the annual number of new patients with cancer. Cancer is a huge and growing contributor to the burden of disease and premature death within the European Union (EU). One in four of all deaths in the EU is attributable to cancer, and in the age range 45-64 years, the figure is almost one in two deaths. The 27 EU Member States differ greatly in cancer incidence, mortality and survival. Yet at least one-third of the cancer burden is preventable and a further third can be detected early and treated effectively, even on the basis of existing knowledge. "Cancer", however,…

Cancer ResearchEconomic growthPresidencyService delivery frameworkWorld Health OrganizationAge DistributionCancer controlEnvironmental protectionNeoplasmsmedia_common.cataloged_instanceMedicinePopulation growthHumansMass ScreeningEuropean UnionRegistriesEuropean unionMortalityPopulation GrowthHealth policymedia_commonbusiness.industryCancermedicine.diseaseIntegrated careEuropePrimary PreventionOncologybusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Registration of childhood cancer: Moving towards pan-European coverage?

2015

Cancer is relatively rare in childhood, but it contributes considerably to childhood mortality, years of life lost per person and late effects in survivors. Large populations need to be covered to set up meaningful studies of these rare conditions. Cancer registries ensure cancer surveillance, thus providing the basis for research as well as policy decisions. In this paper we examine coverage of childhood population by cancer registries in Europe and encourage national cancer registration. Over 200 cancer registries in various stages of development were identified as collecting data on childhood cancer patients in Europe. They cover 52% of the childhood population in the World Health Organi…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentChildhood cancerPopulation610 Medicine & healthWorld Health OrganizationNeoplasmsEnvironmental healthHumansMedicinemedia_common.cataloged_instance1306 Cancer ResearchEuropean UnionRegistriesAge of OnsetEuropean unionChildeducationmedia_commoneducation.field_of_studyData collectionbusiness.industryIncidence (epidemiology)Infant NewbornInfantCancer10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseaseEuropeYears of potential life lostOncologyChild PreschoolData qualityPractice Guidelines as Topic2730 OncologybusinessEuropean Journal of Cancer
researchProduct

Factors associated with decision-making on prophylactic hysterectomy and attitudes towards gynecological surveillance among women with Lynch syndrome…

2020

AbstractTo prevent endometrial carcinoma in Lynch syndrome (LS), regular gynecological surveillance visits and prophylactic surgery are recommended. Previous data have shown that prophylactic hysterectomy is an effective means of cancer prevention, while the advantages and disadvantages of surveillance are somewhat unclear. We aimed to evaluate female LS carriers’ attitudes towards regular gynecological surveillance and factors influencing their decision-making on prophylactic surgery that have not been well documented. Pain experienced during endometrial biopsies was also evaluated. Postal questionnaires were sent to LS carriers undergoing regular gynecological surveillance. Questionnaires…

Cancer ResearchSURGERYmedicine.medical_treatmentPain Procedural0302 clinical medicineSurveys and QuestionnairesEpidemiologyProphylactic surgeryFinlandGenetics (clinical)Aged 80 and overRISKSurveillancemedicine.diagnostic_testObstetricsMiddle Aged16. Peace & justiceProphylactic SurgeryLynch syndrome3. Good healthDNA-Binding Proteinsprophylactic surgeryMutS Homolog 2 ProteinOncologyPatient Satisfaction030220 oncology & carcinogenesissurveillanceFemaleOriginal Article030211 gastroenterology & hepatologyMutL Protein Homolog 1AdultHeterozygotemedicine.medical_specialtyDecision Making3122 CancersHNPCCHysterectomyehkäisevä lääketiede03 medical and health sciencesSyöpätaudit - CancersGeneticsmedicineCarcinomaHumansGenetic TestingLynchin oireyhtymäAgedRetrospective StudiesHysterectomyCancer preventionbusiness.industryEndometrial cancerENDOMETRIAL CANCERmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisEndometrial NeoplasmsLynch syndromebusinessEndometrial biopsy
researchProduct

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

2013

Human papillomavirus (HPV) 58 accounts for a notable proportion of cervical cancers in East Asia and parts of Latin America, but it is uncommon elsewhere. The reason for such ethnogeographical predilection is unknown. In our study, nucleotide sequences of E6 and E7 genes of 401 HPV58 isolates collected from 15 countries/cities across four continents were examined. Phylogenetic relationship, geographical distribution and risk association of nucleotide sequence variations were analyzed. We found that the E6 genes of HPV58 variants were more conserved than E7. Thus, E6 is a more appropriate target for type-specific detection, whereas E7 is more appropriate for strain differentiation. The frequ…

Cancer ResearchSettore MED/07 - Microbiologia E Microbiologia Clinicacervical cancerSettore MED/06 - Oncologia MedicaPapillomavirus E7 ProteinsUterine Cervical NeoplasmsCervix UteriphylogenyPolymerase Chain ReactionViralPapillomaviridaePapillomaviridaePhylogenyCancerOncogene ProteinsCervical cancerGeneticsTumorGeographybiologyNucleic acid sequenceDNA NeoplasmPrognosisInfectious DiseasesOncologyHIV/AIDSFemaleHPVhuman papillomavirus type 58 E6 and E7 sequence variationsOncology and CarcinogenesisCervical intraepithelial neoplasiaRisk AssessmentArticleVaccine Relatedoncogenic riskClinical ResearchPhylogeneticsGenetic variationGeneticsBiomarkers TumormedicineHumansOncology & CarcinogenesisGenePreventionPapillomavirus InfectionsGenetic VariationInternational AgenciesDNAOncogene Proteins ViralOdds ratioUterine Cervical Dysplasiamedicine.diseasebiology.organism_classificationVirologyvariantNeoplasmSexually Transmitted InfectionsCapsid ProteinsBiomarkersFollow-Up Studies
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct

Foreword: Implementing cancer prevention in Europe

2010

The understanding of risk factors underpinning the aetiology of many common cancers is well established, yet the conversion of this knowledge into prevention lags considerably behind. The title of this Special Issue - Implementing cancer prevention in Europe - captures the central theme within; namely, the translation of cancer epidemiology into public health policy. The Special Issue is supported by focused evidence-based case studies of how these processes might be best taken forward. (C) 2010 Published by Elsevier Ltd.

Cancer ResearchUnderpinningCancer preventionOncologySDG 3 - Good Health and Well-beingbusiness.industryEpidemiology of cancerMedicinePublic relationsbusinessPublic health policyTheme (narrative)European Journal of Cancer
researchProduct

The Porto European Cancer Research Summit 2021.

2021

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…

Cancer Researchmedicine.medical_specialty:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]infrastructures for translational cancer researchDeclarationTranslational researchContext (language use)comprehensive cancer centresMeeting Reportclinical/prevention trials:profesiones sanitarias::medicina::medicina clínica::medicina de precisión [DISCIPLINAS Y OCUPACIONES]Translational Research Biomedicaloutcomes research:neoplasias [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]cancer research/care/prevention continuumNeoplasmsPolitical scienceGeneticsmedicineHumansmedia_common.cataloged_instance:Health Occupations::Medicine::Clinical Medicine::Precision Medicine [DISCIPLINES AND OCCUPATIONS]Medicina personalitzadaPrecision MedicineEuropean unionRC254-282media_commongeographySummitgeography.geographical_feature_categoryHealth economics:Natural Science Disciplines::Science::Research::Biomedical Research [DISCIPLINES AND OCCUPATIONS]Neoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineCancer MissionEuropescience policy:Neoplasms [DISEASES]Medicina - InvestigacióOncologyQuality of LifeCancer researchMolecular MedicineScience policyCàncer - PrevencióOutcomes research:disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica [DISCIPLINAS Y OCUPACIONES]
researchProduct